Sanofi, Re­gen­eron win a cru­cial stay of ex­e­cu­tion on Pralu­ent

Sanofi and Re­gen­eron’s Pralu­ent gets to stay on the mar­ket while the part­ners fight an­oth­er day in court for the PC­SK9 fran­chise.

Re­gen­eron $REGN an­nounced just af­ter the mar­ket closed on Wednes­day that the US Court of Ap­peals had grant­ed a stay of a con­tro­ver­sial de­ci­sion in ear­ly Jan­u­ary that Pralu­ent vi­o­lat­ed Am­gen’s patents on the ri­val PC­SK9 cho­les­terol drug Repatha, war­rant­i­ng its re­moval from the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER